BI 1206

Drug Profile

BI 1206

Alternative Names: 6G 11; BI-1206

Latest Information Update: 21 Sep 2016

Price : $50

At a glance

  • Originator BioInvent International
  • Developer BioInvent International; University of Southampton
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action CD20 antigen modulators; Fc gamma receptor IIB antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma

Most Recent Events

  • 19 Sep 2016 Phase-I/II clinical trials in Chronic lymphocytic leukaemia (Combination therapy, Monotherapy) in United Kingdom (Parenteral)
  • 19 Sep 2016 Phase-I/II clinical trials in Non-Hodgkin's lymphoma (Combination therapy, Monotherapy) in United Kingdom (Parenteral)
  • 26 Jul 2016 BioInvent receives a regulatory approval for Chronic lymphocytic leukaemia and Non-Hodgkin lymphoma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top